The earnings call conveyed a positive sentiment with strong revenue growth, successful product launches, and strategic financial maneuvers. However, there were some concerns about gross margin decline and delayed EBITDA positivity.

Company Guidance -

Q3 2025

In the second quarter of 2025, TriSalus Life Sciences achieved notable financial and strategic milestones, reflected in a 52% year-over-year increase in net sales, amounting to $11.2 million, and a 22% sequential growth from the first quarter. The company launched the TriNav FLX infusion system and completed a $22 million private placement, strengthening its balance sheet. TriSalus also expanded its market opportunity with the issuance of code C8004 by the Centers for Medicare and Medicaid Services, which doubled the reimbursable use of their technology. The company remains focused on broadening the clinical and commercial reach of its pressure-enabled drug delivery platform across various tumor types and advancing nelitolimod through strategic partnerships. TriSalus reiterated its guidance of 50% revenue growth for 2025, while strategically delaying EBITDA positivity until 2026 due to ongoing investments. The company ended the quarter with $26.5 million in cash, positioning itself for continued growth and innovation in the medical device and oncology sectors.

Strong Revenue Growth

TriSalus reported a 52% increase in net sales year-over-year to $11.2 million and a 22% sequential gain over Q1 2025.

TriNav FLX Infusion System Launch

The company successfully launched the TriNav FLX infusion system, which exceeded internal projections and contributed to commercial momentum.

Successful Private Placement

Completed a $22 million private placement with healthcare-focused institutional investors, strengthening the balance sheet.

New Medicare Coverage Code

Centers for Medicare and Medicaid Services issued code C8004, doubling the reimbursable use of TriNav technology.

Operational Efficiency Improvements

Efforts to streamline G&A costs and focus on device innovation expected to reduce ongoing R&D expenses.

Positive Clinical Results

TriNav products showed 100% technical and clinical success in a recent study, with significant thyroid shrinkage and normalization of thyroid function.

TriSalus Life Sciences (TLSI) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

TLSI Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 18, 2025	2025 (Q3)	-0.14 / -	-0.12	―	―	―
Aug 12, 2025	2025 (Q2)	-0.21 / -0.27	-0.21	-28.57% (-0.06)	―
May 15, 2025	2025 (Q1)	-0.22 / -0.39	-0.6	35.00% (+0.21)	―
Mar 27, 2025	2024 (Q4)	-0.32 / -0.40	-1.56	74.36% (+1.16)	―
Nov 14, 2024	2024 (Q3)	-0.35 / -0.12	-0.13	7.69% (+0.01)	―
Aug 15, 2024	2024 (Q2)	-0.46 / -0.21	-0.89	76.40% (+0.68)	―
May 15, 2024	2024 (Q1)	- / -	-0.055	―	―
Apr 01, 2024	2023 (Q4)	-0.58 / -0.60	-0.055	-990.91% (-0.54)	―
Nov 14, 2023	2023 (Q3)	- / -0.13	0.021	-719.05% (-0.15)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

TLSI Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 12, 2025	$3.65	$3.95	+8.22%
May 15, 2025	$4.90	$5.11	+4.29%
Mar 27, 2025	$5.58	$5.50	-1.43%
Nov 14, 2024	$4.50	$4.01	-10.89%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does TriSalus Life Sciences (TLSI) report earnings?

TriSalus Life Sciences (TLSI) is schdueled to report earning on Nov 18, 2025, Before Open (Confirmed).

What is TriSalus Life Sciences (TLSI) earnings time?

TriSalus Life Sciences (TLSI) earnings time is at Nov 18, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is TLSI EPS forecast?

TLSI EPS forecast for the fiscal quarter 2025 (Q3) is -0.14.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing